Thu Sep 12 01:04:44 UTC 2024: ## ADMA Biologics Director Executes Stock Sale and Purchase Amidst Company Growth

**Ramsey, NJ – September 10, 2024** – ADMA Biologics, Inc. (NASDAQ: ADMA) is making headlines for both its recent financial performance and a significant insider transaction. Lawrence P. Guiheen, a director on the company’s board, sold 9,000 shares of ADMA stock on September 9th for a total of approximately $166,188. Guiheen also exercised options to acquire 9,000 shares at $10.8 per share, totaling $97,200. While the sale was significant, Guiheen still holds 153,941 shares in the company, including restricted stock units set to vest next year.

This insider activity comes as ADMA Biologics is experiencing strong growth. The company recently repaid $30 million of its revolving credit facility, reducing total gross debt by 22%. Moreover, ADMA reported a substantial 78% year-over-year revenue increase in the second quarter, reaching $107.2 million, and a net income of $32.1 million. This impressive performance has led H.C. Wainwright to raise its price target for ADMA Biologics to $18.00.

In other news, ADMA Biologics has appointed Brad Tade as its new Chief Financial Officer and Treasurer. The company has also amended its bylaws to make it easier for shareholders to remove a director with cause.

These developments underscore ADMA Biologics’ commitment to financial growth, operational excellence, and good corporate governance. Investors are closely monitoring the company’s progress, particularly in light of the recent insider transaction. ADMA Biologics currently boasts a market capitalization of $3.96 billion and has seen impressive revenue growth in recent months. The company’s financial performance and growth prospects suggest a promising future for ADMA Biologics. For those seeking a deeper dive into the company’s financial intricacies, InvestingPro offers comprehensive insights.

Read More